Literature DB >> 23813049

Molecular cloning, expression, and in silico structural analysis of guinea pig IL-17.

Vijaya R Dirisala1, Amminikutty Jeevan, Suresh K Ramasamy, David N McMurray.   

Abstract

Interleukin-17A (IL-17A) is a potent proinflammatory cytokine and the signature cytokine of Th17 cells, a subset which is involved in cytokine and chemokine production, neutrophil recruitment, promotion of T cell priming, and antibody production. IL-17 may play an important role in tuberculosis and other infectious diseases. In preparation for investigating its role in the highly relevant guinea pig model of pulmonary tuberculosis, we cloned guinea pig IL-17A for the first time. The complete coding sequence of the guinea pig IL-17A gene (477 nucleotides; 159 amino acids) was subcloned into a prokaryotic expression vector (pET-30a) resulting in the expression of a 17 kDa recombinant guinea pig IL-17A protein which was confirmed by mass spectrometry analysis. Homology modeling of guinea pig IL-17A revealed that the three-dimensional structure resembles that of human IL-17A. The secondary structure predicted for this protein showed the presence of one extra helix in the N-terminal region. The expression profile of IL-17A was analyzed quantitatively in spleen, lymph node, and lung cells from BCG-vaccinated guinea pigs by real-time PCR. The guinea pig IL-17A cDNA and its recombinant protein will serve as valuable tools for molecular and immunological studies in the guinea pig model of pulmonary TB and other human diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23813049     DOI: 10.1007/s12033-013-9679-z

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  44 in total

Review 1.  Disease model: pulmonary tuberculosis.

Authors:  D N McMurray
Journal:  Trends Mol Med       Date:  2001-03       Impact factor: 11.951

2.  Determining the yield and quality of purified RNA.

Authors:  Donald C Rio; Manuel Ares; Gregory J Hannon; Timothy W Nilsen
Journal:  Cold Spring Harb Protoc       Date:  2010-06

Review 3.  The success and failure of BCG - implications for a novel tuberculosis vaccine.

Authors:  Peter Andersen; T Mark Doherty
Journal:  Nat Rev Microbiol       Date:  2005-08       Impact factor: 60.633

4.  In-gel digestion for mass spectrometric characterization of proteins and proteomes.

Authors:  Andrej Shevchenko; Henrik Tomas; Jan Havlis; Jesper V Olsen; Matthias Mann
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages.

Authors:  D V Jovanovic; J A Di Battista; J Martel-Pelletier; F C Jolicoeur; Y He; M Zhang; F Mineau; J P Pelletier
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

6.  Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.

Authors:  Simone C de Cassan; Ansar A Pathan; Clare R Sander; Angela Minassian; Rosalind Rowland; Adrian V S Hill; Helen McShane; Helen A Fletcher
Journal:  Clin Vaccine Immunol       Date:  2010-05-19

7.  Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris.

Authors:  Yorihisa Kotobuki; Atsushi Tanemura; Lingli Yang; Saori Itoi; Mari Wataya-Kaneda; Hiroyuki Murota; Minoru Fujimoto; Satoshi Serada; Tetsuji Naka; Ichiro Katayama
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-10       Impact factor: 4.693

8.  IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells.

Authors:  J Witowski; K Pawlaczyk; A Breborowicz; A Scheuren; M Kuzlan-Pawlaczyk; J Wisniewska; A Polubinska; H Friess; G M Gahl; U Frei; A Jörres
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

9.  Recombinant guinea pig CCL5 (RANTES) differentially modulates cytokine production in alveolar and peritoneal macrophages.

Authors:  Troy A Skwor; Hyosun Cho; Craig Cassidy; Teizo Yoshimura; David N McMurray
Journal:  J Leukoc Biol       Date:  2004-09-17       Impact factor: 4.962

10.  Lung macrophages from bacille Calmette-Guérin-vaccinated guinea pigs suppress T cell proliferation but restrict intracellular growth of M. tuberculosis after recombinant guinea pig interferon-gamma activation.

Authors:  A Jeevan; K Majorov; K Sawant; H Cho; D N McMurray
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

View more
  6 in total

1.  Prokaryotic Expression, In Vitro Biological Analysis, and In Silico Structural Evaluation of Guinea Pig IL-4.

Authors:  Madhavan Omanakuttan; Hanumohan R Konatham; Vijaya R Dirisala; Amminikutty Jeevan; Shradha Mawatwal; Rohan Dhiman; Lan H Ly; David McMurray
Journal:  Mol Biotechnol       Date:  2020-02       Impact factor: 2.695

Review 2.  The guinea pig model for tick-borne spotted fever rickettsioses: A second look.

Authors:  John V Stokes; David H Walker; Andrea S Varela-Stokes
Journal:  Ticks Tick Borne Dis       Date:  2020-08-07       Impact factor: 3.744

3.  Molecular and biochemical characterization of recombinant guinea pig tumor necrosis factor-alpha.

Authors:  Vijaya R Dirisala; Amminikutty Jeevan; Lan H Ly; David N McMurray
Journal:  Mediators Inflamm       Date:  2015-04-27       Impact factor: 4.711

Review 4.  Interleukin 17-Mediated Host Defense against Candida albicans.

Authors:  Florian Sparber; Salomé LeibundGut-Landmann
Journal:  Pathogens       Date:  2015-08-12

Review 5.  Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis.

Authors:  Wenping Gong; Yan Liang; Xueqiong Wu
Journal:  Biomed Res Int       Date:  2020-01-02       Impact factor: 3.411

Review 6.  A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.

Authors:  Helen McShane; Ann Williams
Journal:  Tuberculosis (Edinb)       Date:  2013-12-01       Impact factor: 3.131

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.